Albiruni Abdul Razak

Author

Also Known As

A. Abdul Razak, Albiruni A. Razak, Albiruni ABDUL RAZAK, Albiruni Abdul Razak

Publications

221

Citations

H-Index

Concepts

All Affiliations

Albiruni Abdul Razak is an author at Princess Margaret Cancer Centre specializing in cancer research, molecular diagnostics, and engineering.

#	Concept	H-Index	Publications	Citations
1	Engineering	1	1	31
2	Medicine	1	1	31
3	Pathology	1	1	31
4	Cancer Genetics	1	1	31
5	Systems Biology	1	1	31

Albiruni Abdul Razak

Publications

204

Citations

H-Index

Page 1

	Year	Citations
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay, Journal of Clinical Oncology	2022	104
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial Mrinal M. Gounder, Albiruni Abdul Razak, Neeta Somaiah, Journal of Clinical Oncology	2022	37
537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers María Vieito, Anna Spreafico, Víctor Moreno, Annals of Oncology EngineeringAdvanced CancersMedicinePathologyCancer Biology	2020	31
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib Hans Gelderblom, Albiruni Abdul Razak, Matthew H. Taylor, Clinical Cancer Research	2024	22
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study Hans Gelderblom, Robin L. Jones, Jean‐Yves Blay, European Journal of Cancer	2023	10

Page 1